Skip to main content

Table 2 Correlation between the factors and clinicopathologic characteristics in HCC in TCGA dataset (n = 363)

From: Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma

Clinical features

Case

RAD52 level (RSEM; mean ± SD)

P value

Sample

 LIHC

363

6.4606 ± 0.6778

P < 0.05*

 Normal

50

6.0250 ± 0.5742

 

Age at diagnosis (years)

 > 45

314

6.4371 ± 0.6918

P > 0.05

 ≤ 45

48

6.6329 ± 0.5475

 

 Unknown

1

  

Gender

 Male

246

6.3721 ± 0.6948

P < 0.05*

 Female

117

6.6466 ± 0.6020

 

The AFP in serum

 > 20 ng/ml

129

6.5403 ± 0.6778

P > 0.05

 ≤ 20 ng/ml

143

6.4050 ± 0.6319

 

 Unknown

91

  

Clinical stage

 I–II

251

6.4353 ± 0.6493

P > 0.05

 III–IV

88

6.5033 ± 0.7782

 

 Unknown

24

  

Child–Pugh classification

 A

213

6.4195 ± 0.7080

P > 0.05

 B

21

6.4685 ± 0.5537

 

 C

1

  

 Unknown

128

  

HBsAg infection

 Yes

226

6.4981 ± 0.6733

P > 0.05

 No

122

6.4139 ± 0.6543

 

 Unknown

15

  

Lymph node

 N0

246

6.4788 ± 0.6713

P > 0.05

 N1

3

6.8001 ± 1.0916

 

 Unknown

114

  

Metastasis

 M0

260

6.4512 ± 0.6827

P > 0.05

 M1

4

6.0975 ± 0.5427

 

 Unknown

99

  
  1. TCGA The Cancer Genome Atlas, LIHC liver hepatocellular carcinoma, HCC hepatocellular carcinoma, RSEM RNA-seq by expectation-maximization, RAD52 radiation sensitive 52, AFP alpha fetoprotein, HBsAg hepatitis B surface antigen, SD standard deviation
  2. * P < 0.05
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us